This page provides an investment landscape analysis of protein kinase inhibitors being developed for neurodegenerative disease treatment.
Protein kinases represent one of the most druggable target families in drug development, with over 75 FDA-approved kinase inhibitors across oncology and inflammatory diseases[1]. In neurodegeneration, kinase dysregulation plays a critical role in pathological processes including tau hyperphosphorylation, neuroinflammation, and neuronal death. This investment landscape analyzes the current pipeline, commercial opportunities, and strategic considerations for kinase inhibitor therapeutics in Alzheimer's disease, Parkinson's disease, ALS, and related disorders.
The field has seen significant academic and commercial interest, particularly in glycogen synthase kinase-3 beta (GSK-3β), cyclin-dependent kinase 5 (CDK5), and dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). While no kinase inhibitor has yet received FDA approval for a neurodegenerative indication, multiple compounds have advanced to clinical trials, and recent mechanistic insights have renewed investor interest.
Protein kinases regulate numerous cellular processes critical to neuronal health, including:
Investment prioritizes kinases meeting these criteria:
Glycogen synthase kinase-3 beta (GSK-3β) is the most advanced kinase target in neurodegeneration, with over 20 years of clinical development.
| Compound | Company | Status | Indication | Notes |
|---|---|---|---|---|
| Tideglusib (NP-12) | NeuroPharma/Advent Health | Phase 2 completed | AD, PSP | Oral, non-ATP competitive |
| Lithium | Generic | Off-patent | Bipolar/ND | Mood stabilizer, repurposed |
| AR-A014418 | AstraZeneca | Preclinical | Research compound | Selective GSK-3β inhibitor |
| CHIR99021 | Multiple | Research | Tool compound | Selective GSK-3β inhibitor |
| VP2.51 | Vivan Therapeutics | Phase 1 | AD | Brain-penetrant oral |
Cyclin-dependent kinase 5 (CDK5) is critical for tau phosphorylation and neuronal development. Unlike other CDKs, CDK5 is neuron-specific and activated by p35/p39 regulatory subunits.
| Compound | Company | Status | Indication | Notes |
|---|---|---|---|---|
| Roscovitine (Seliciclib) | Cyclacel | Phase 2 completed | Various, ND research | Multi-CDK inhibitor |
| Dinaciclib | Merck | Phase 1/2 | Oncology/ND | Potent CDK5/2/9 inhibitor |
| AT-7519 | Astex/University of Edinburgh | Preclinical | ND research | CDK5 inhibitor |
| CYC-202 (Seliciclib) | Cyclacel | Phase 1/2 | NSCLC, AML | Oral bioavailability |
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) phosphorylates tau, alpha-synuclein, and regulates autophagy. It's located on chromosome 21 and implicated in Down syndrome-related neurodegeneration.
| Compound | Company | Status | Indication | Notes |
|---|---|---|---|---|
| Leuvuscillin (ALK5i) | Multiple | Research | Tool compound | Broad kinase inhibitor |
| DYRKI-1 | EIP Pharma | Preclinical | ND research | Selective DYRK1A inhibitor |
| Harmine | Multiple | Research | Natural product | DYRK1A inhibitor |
| AX-776 | Axial Therapeutics | Preclinical | ND | Brain-penetrant |
Protein kinase C (PKC) isoforms regulate synaptic plasticity, memory, and neuroprotection. Certain PKC activators have shown neuroprotective effects.
| Compound | Company | Status | Indication | Notes |
|---|---|---|---|---|
| Brimastumab (HH-10) | Lundbeck | Research | ND | PKC-δ modulator |
| Bryostatin | Neurotrope | Phase 2 | AD | PKC activator |
| NGX-426 | Archer | Phase 1 | ND | Oral PKC modulator |
The neurodegenerative disease drug market represents a significant commercial opportunity:
| Disease | Global Market (2024) | Projected (2030) | CAGR |
|---|---|---|---|
| Alzheimer's Disease | $4.5B | $13.8B | 18% |
| Parkinson's Disease | $5.8B | $9.2B | 8% |
| ALS | $1.1B | $1.9B | 9% |
| PSP/MSA | $0.3B | $0.6B | 12% |
Source: Multiple industry analysts
Major Players in Kinase Inhibitor Development:
| Company | Programs | Stage | Focus |
|---|---|---|---|
| Vivan Therapeutics | VP2.51 | Phase 1 | GSK-3β |
| EIP Pharma | DYRK1A inhibitors | Preclinical | DYRK1A |
| Cyclacel | Roscovitine | Phase 2 | CDK5 |
| Axial Therapeutics | AX-776 | Preclinical | DYRK1A |
| Neurotrope | Bryostatin | Phase 2 | PKC |
Protein kinase inhibitors represent a mature but underutilized approach to neurodegeneration. The scientific rationale is strong, with clear links between kinase activity and disease pathology. However, the field has been hampered by:
High Priority:
Watch List:
Avoid:
The 2025-2030 period may represent a turning point for kinase inhibitors in neurodegeneration, particularly as anti-amyloid and anti-tau antibodies reach market and inform combination strategies. Investors should monitor clinical readouts from Vivan Therapeutics, academic partnerships at major research universities, and government funding announcements for novel target validation.
Last updated: 2026-03-14
Investment landscape analysis - NeuroWiki
Wu, P. et al. Kinase inhibitors in clinical oncology: a comprehensive review. Nature Reviews Clinical Oncology. 2023. ↩︎
Hanger, D.P. et al. GSK-3: a key target for the development of novel therapeutics for Alzheimer's disease. Progress in Molecular Biology and Translational Science. 2020. ↩︎
Song, G.J. et al. CDK5 as a therapeutic target in neurodegenerative diseases. Neurobiology of Disease. 2021. ↩︎
Li, L. et al. Kinase regulation of autophagy in neurodegeneration. Autophagy. 2019. ↩︎
Wayman, G.A. et al. Synaptic plasticity, memory and the kinases that regulate them. Neurobiology of Learning and Memory. 2011. ↩︎
Herrup, K. et al. Cell cycle activation in neurodegenerative disease. Nature Reviews Neuroscience. 2004. ↩︎
Lovestone, S. et al. A phase II trial of tideglusib in progressive supranuclear palsy. Journal of Neurology, Neurosurgery & Psychiatry. 2015. ↩︎
del Ser, T. et al. Treatment of Alzheimer's disease with tideglusib: a phase 2 clinical trial. Neurobiology of Aging. 2013. ↩︎
Matsunaga, S. et al. Lithium and cognitive function: a systematic review. Journal of Alzheimer's Disease. 2019. ↩︎
Pate, K.M. et al. CDK5 as a therapeutic target in Alzheimer's disease. Current Alzheimer Research. 2017. ↩︎